Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA
Artiva Biotherapeutics Stock Slides Despite Positive Trial Data
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Short Interest Down 28.5% in January
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $19.00 Average PT from Brokerages
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Growth in Short Interest
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $19.00 Consensus PT from Analysts
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
Artiva (ARTV) Q2 Loss Widens 19.7%
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares
U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week